Analyst Price Targets — PHAT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 5:51 pm | Annabel Samimy | Stifel Nicolaus | $28.00 | $13.62 | StreetInsider | Stifel Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT) |
| December 11, 2025 9:10 pm | Martin Auster | Raymond James | $28.00 | $14.56 | TheFly | Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James |
| December 8, 2025 9:27 pm | Jenna Davidner | Barclays | $16.00 | $14.90 | TheFly | Phathom Pharmaceuticals initiated with an Equal Weight at Barclays |
| October 31, 2025 1:26 pm | Chase Knickerbocker | Craig-Hallum | $22.00 | $13.76 | TheFly | Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum |
| October 31, 2025 10:10 am | — | H.C. Wainwright | $26.00 | $13.31 | TheFly | Phathom Pharmaceuticals price target raised to $26 from $20 at H.C. Wainwright |
| October 30, 2025 4:03 pm | Yatin Suneja | Guggenheim | $20.00 | $13.31 | StreetInsider | Phathom Pharmaceuticals (PHAT) PT Raised to $20 at Guggenheim |
| March 7, 2025 2:16 pm | — | Guggenheim | $18.00 | $5.06 | TheFly | Phathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim |
| August 8, 2024 4:17 pm | Paul Choi | Goldman Sachs | $12.00 | $11.75 | StreetInsider | Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs |
| July 19, 2024 10:02 am | Matthew Caufield | H.C. Wainwright | $28.00 | $10.95 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT) |
| May 2, 2024 4:13 pm | Annabel Samimy | Stifel Nicolaus | $24.00 | $9.76 | TheFly | Phathom Pharmaceuticals initiated with a Buy at Stifel |
Latest News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.79 per share a year ago.
Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and…
FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MA…
FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHAT.
U.S. House Trading
No House trades found for PHAT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.